Compare Enveric Biosciences Inc (ENVB) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Las Vegas Sands Corp. — how do they compare? Enveric Biosciences Inc trades at $1.38 (market cap $5.32M), while Las Vegas Sands Corp. trades at $45.32 (market cap $29.68B). The key difference: Las Vegas Sands Corp. is far larger — about 5578.9× Enveric Biosciences Inc's market cap, and Las Vegas Sands Corp. pays a 2.46% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | LVS | |
|---|---|---|
Market Cap | $5.32M | $29.68B |
Sector | Health | Consumer Cyclical |
52-Week High | $17.40 | $69.49 |
52-Week Low | $1.28 | $44.78 |
Enterprise Value | $408.82K | $42.07B |
Dividend Yield | — | 2.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
LVS trades at $44.78, down 2.44% with bearish technical signals, though fundamentals show strength with consistent earnings beats and revenue growth from $11.3B in 2024 to $13.0B in 2025. The company maintains solid profitability with 49.59% gross margins and 13.41% net income margin, supported by strong cash flow generation of $3.02B from operations in 2025.
Analyst consensus remains strongly bullish with 61% buy ratings and $65.40 price target, representing 46% upside potential. Key risks include high debt levels with 73.15% debt-to-asset ratio and Macau regulatory exposure, while recent ESG achievements and dividend payments provide stability for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
